Invention Grant
- Patent Title: Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
-
Application No.: US16710533Application Date: 2019-12-11
-
Publication No.: US10653697B2Publication Date: 2020-05-19
- Inventor: Scott Bone , Tracy Lee Gaebele , Yu Pu , Lianfeng Huang
- Applicant: Celgene Corporation
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: A61K31/52
- IPC: A61K31/52 ; A61K9/48 ; A61K47/20 ; A61K47/22 ; A61K9/20 ; A61K31/522 ; A61P35/00
![Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide](/abs-image/US/2020/05/19/US10653697B2/abs.jpg.150x150.jpg)
Abstract:
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Information query
IPC分类: